Comments to FDA: Proprietary Name Reservation for Drug Products

Share page:

Comments | Oct 27, 2014

Docket Number:
FDA-2014-N-1008

In principle, CHPA supports an early approval program for proposed proprietary drug names. However, should FDA decide to implement a program, we expect that FDA would publish a draft Guidance for Industry and we would provide further comment based on the criteria.

Related Posts

Press Releases and Statements

CHPA Welcomes Three Consumer Healthcare Industry Members

Press Releases and Statements

CHPA Statement: OTC Pain Relievers and COVID-19 Vaccines